Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2020
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,111
+22.37%
|
-
|
|
May 07
2020
|
Leslie A Brun Director |
SELL
Open market or private sale
|
Direct |
5,000
-71.96%
|
$375,000
$75.46 P/Share
|
|
May 07
2020
|
Leslie A Brun Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+41.85%
|
-
|
|
May 07
2020
|
Wendell P Weeks Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$380,000
$76.02 P/Share
|
|
May 07
2020
|
Wendell P Weeks Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
-
|
|
May 05
2020
|
Michael Nally EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,020
-8.46%
|
$77,520
$76.86 P/Share
|
|
May 05
2020
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,345
+16.29%
|
$178,220
$76.86 P/Share
|
|
May 05
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,617
-5.5%
|
$122,892
$76.86 P/Share
|
|
May 05
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
3,283
+10.05%
|
$249,508
$76.86 P/Share
|
|
May 05
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
458
-6.27%
|
$34,808
$76.86 P/Share
|
|
May 05
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,290
+15.01%
|
$98,040
$76.86 P/Share
|
|
May 05
2020
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
1,848
-2.24%
|
$140,448
$76.86 P/Share
|
|
May 05
2020
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
3,752
+4.34%
|
$285,152
$76.86 P/Share
|
|
May 04
2020
|
Jennifer Zachary EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,843
-29.96%
|
$218,911
$77.67 P/Share
|
|
May 04
2020
|
Jennifer Zachary EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,772
+37.82%
|
$444,444
$77.67 P/Share
|
|
May 04
2020
|
Michael Nally EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
565
-5.5%
|
$43,505
$77.67 P/Share
|
|
May 04
2020
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,298
+11.22%
|
$99,946
$77.67 P/Share
|
|
May 04
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
597
-2.23%
|
$45,969
$77.67 P/Share
|
|
May 04
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,212
+4.34%
|
$93,324
$77.67 P/Share
|
|
May 04
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
238
-3.81%
|
$18,326
$77.67 P/Share
|
|
May 04
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
692
+9.97%
|
$53,284
$77.67 P/Share
|
|
May 04
2020
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
938
-1.18%
|
$72,226
$77.67 P/Share
|
|
May 04
2020
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
1,904
+2.33%
|
$146,608
$77.67 P/Share
|
|
May 03
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
529
-8.69%
|
$40,733
$77.67 P/Share
|
|
May 03
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,541
+20.2%
|
$118,657
$77.67 P/Share
|
|
May 03
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
431
-1.66%
|
$33,187
$77.67 P/Share
|
|
May 03
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
875
+3.26%
|
$67,375
$77.67 P/Share
|
|
Feb 28
2020
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
33,396
+16.33%
|
$2,538,096
$76.56 P/Share
|
|
Feb 28
2020
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
15,785
+16.9%
|
$1,199,660
$76.56 P/Share
|
|
Feb 28
2020
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
4,905
+5.97%
|
$372,780
$76.56 P/Share
|
|
Feb 28
2020
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
14,374
+14.2%
|
$1,092,424
$76.56 P/Share
|
|
Feb 28
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,659
+26.88%
|
$126,084
$76.56 P/Share
|
|
Feb 28
2020
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
119,291
+13.21%
|
$9,066,116
$76.56 P/Share
|
|
Feb 28
2020
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,371
+14.24%
|
$560,196
$76.56 P/Share
|
|
Feb 28
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
4,269
+14.56%
|
$324,444
$76.56 P/Share
|
|
Feb 28
2020
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,328
+27.2%
|
$252,928
$76.56 P/Share
|
|
Feb 28
2020
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
35,049
+14.05%
|
$2,663,724
$76.56 P/Share
|
|
Jan 13
2020
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
102,073
-73.38%
|
$9,084,497
$89.34 P/Share
|
|
Jan 13
2020
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
82,548
+25.5%
|
-
|
|
Oct 30
2019
|
James H Scholefield EVP,Chief Info&Digital Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,294
-37.55%
|
$364,990
$85.1 P/Share
|
|
Oct 30
2019
|
James H Scholefield EVP,Chief Info&Digital Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,436
+50.0%
|
-
|
|
Oct 30
2019
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
1,127
-1.54%
|
$95,795
$85.1 P/Share
|
|
Oct 30
2019
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
2,287
+3.04%
|
-
|
|
Oct 30
2019
|
Michael Nally EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
652
-10.52%
|
$55,420
$85.1 P/Share
|
|
Oct 30
2019
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,287
+26.96%
|
-
|
|
Oct 30
2019
|
Steven Mizell EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,567
-34.26%
|
$133,195
$85.1 P/Share
|
|
Oct 30
2019
|
Steven Mizell EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,574
+50.0%
|
-
|
|
Aug 09
2019
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
6,427
-8.25%
|
$546,295
$85.09 P/Share
|
|
Aug 09
2019
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
6,427
+7.62%
|
-
|
|
Aug 08
2019
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
31,699
-30.71%
|
$2,694,415
$85.01 P/Share
|